Exelixis Receivables 2010-2025 | EXEL

Exelixis receivables for the quarter ending June 30, 2025 were $0.292B, a 26.28% decline year-over-year.

  • Exelixis receivables for 2024 were $0.265B, a 11.81% increase from 2023.
  • Exelixis receivables for 2023 were $0.237B, a 10.53% increase from 2022.
  • Exelixis receivables for 2022 were $0.215B, a 24.01% decline from 2021.

Exelixis Receivables 2010-2025 | EXEL

  • Exelixis receivables for 2024 were $0.265B, a 11.81% increase from 2023.
  • Exelixis receivables for 2023 were $0.237B, a 10.53% increase from 2022.
  • Exelixis receivables for 2022 were $0.215B, a 24.01% decline from 2021.
Related Stocks
Company NameMarket
Cap
AstraZeneca (AZN)$229.7B
Amgen (AMGN)$153.5B
Gilead Sciences (GILD)$149.5B
Vertex Pharmaceuticals (VRTX)$96B
Bristol Myers Squibb (BMY)$93.5B
CSL (CSLLY)$83.2B
GSK (GSK)$76.9B
Regeneron Pharmaceuticals (REGN)$57.9B
Alnylam Pharmaceuticals (ALNY)$57B
Argenex SE (ARGX)$39.1B
BioNTech SE (BNTX)$26.3B
Insmed (INSM)$23.9B
Royalty Pharma (RPRX)$20.3B
Biogen (BIIB)$18.8B
Incyte (INCY)$15.5B
Illumina (ILMN)$14.6B
Genmab (GNMSF)$14.3B
Genmab (GMAB)$13.5B
Ascendis Pharma (ASND)$12B
BioMarin Pharmaceutical (BMRN)$10.9B
QIAGEN (QGEN)$10.7B
Swedish Orphan Biovitrum (BIOVF)$10.6B
Moderna (MRNA)$9.9B
Verona Pharma American Depositary Share (VRNA)$9B
Blueprint Medicines (BPMC)$8.3B
Bio-Techne Corp (TECH)$7.9B
Halozyme Therapeutics (HALO)$7.7B
Exact Sciences (EXAS)$7.7B
Roivant Sciences (ROIV)$7.6B
Guardant Health (GH)$6.8B